The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).
 
Jatin J. Shah
Consulting or Advisory Role - Array BioPharma; Celgene; FORMA Therapeutics; Novartis; Onyx; Takeda
Research Funding - array biopharma (Inst); Celgene (Inst); Millennium (Inst); Novartis (Inst); onyx (Inst)
 
Sundar Jagannath
Honoraria - Bristol-Myers Squibb; Celgene; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Novartis; Sanofi
 
María-Victoria Mateos
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda
Consulting or Advisory Role - Celgene; Janssen
 
Antonio Palumbo
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Genmab; Janssen-Cilag; Millennium; Novartis; Onyx; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genmab; Janssen-Cilag; Millennium; Onyx
 
Uma Kher
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Patricia Maria Marinello
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jesus San Miguel
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen-Ortho; Millennium; MSD; Novartis; Onyx